Alaunos Therapeutics, Inc. (TCRT)

Market Cap	9.76M
Revenue (ttm)	11,000
Net Income (ttm)	-4.07M
Shares Out	1.98M
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,617
Open	5.010
Previous Close	5.010
Day's Range	4.890 - 5.070
52-Week Range	1.314 - 6.900
Beta	-0.79
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2025

About TCRT

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: TCRT
• Website: https://www.alaunos.com

Financial Performance

In 2024, Alaunos Therapeutics's revenue was $10,000, an increase of 100.00% compared to the previous year's $5,000. Losses were -$4.68 million, -86.68% less than in 2023.